Immutep collaborates with Merck to test combination therapy for metastatic NSCLC

From Nasdaq: 2024-06-02 22:32:16

Immutep Limited has partnered with Merck & Co., Inc. to conduct a Phase III trial for the treatment of metastatic NSCLC using eftilagimod alfa, Keytruda, and chemotherapy. This collaboration follows successful Phase II trials treating over 350 patients. Immutep will lead the registrational TACTI-004 study while Merck will supply Keytruda. The agreement allows both companies to market the combination therapy with their respective compounds and pursue marketing authorization. Both companies also retain commercial rights to their compounds for future studies in any therapeutic area.



Read more at Nasdaq: Immutep Collaborates With Merck To Evaluate Efti In Combination Therapy For Metastatic NSCLC